Nordea Investment Management AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Nordea Investment Management AB boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 62,971 shares of the biopharmaceutical company’s stock after buying an additional 15,983 shares during the period. Nordea Investment Management AB owned approximately 0.06% of Regeneron Pharmaceuticals worth $35,112,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of REGN. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Traub Capital Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $38,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. Finally, Berbice Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 8,431 shares of company stock worth $5,733,521 over the last quarter. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Down 0.6%

REGN stock opened at $754.14 on Thursday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $745.46 and a 200-day simple moving average of $633.82. The company has a market capitalization of $79.26 billion, a P/E ratio of 18.06, a PEG ratio of 1.98 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $12.46 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several analyst reports. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Scotiabank increased their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $791.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.